Back to search

Article

Efficacy of third-generation EGFR-TKIs in advanced NSCLC with different T790M statuses tested via ddPCR and NGS

2023-01-19

Abstract excerpt

<h4>Objective: </h4> Third-generation epidermal growth factor receptor ( EGFR )-tyrosine kinase inhibiors (TKIs) is the standard strategy for T790M-positive non-small cell lung cancer (NSCLC). We hypothesize that ddPCR, with a higher sensitivity than NGS, would optimize the treatment strategies in EGFR -TKIs relapsed patients. In this study, we compared the efficacy of third-generation TKIs with various T790M stat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
cc275edb-d3e7-5d83-8276-f6c561a42f68
DOI
10.21203/rs.3.rs-2486337/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficacy of third-generation EGFR-TKIs in advanced NSCLC with different T790M statuses tested via ddPCR and NGSDOI 10.21203/rs.3.rs-2486337/v1
Third-Generation EGFR-TKIs Combined With Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Real-World Study.Semantic proximity
The allele frequency of EGFR T790M in ctDNA predicted clinical outcomes of Osimertinib in non-small cell lung cancer patients from a real-world studySemantic proximity
Comparison of efficacy and safety of second- and third-generation TKIs for non-small-cell lung cancer with uncommon EGFR mutations.Semantic proximity
Optimal First-Line Treatment for EGFR-Mutated NSCLC: A Comparative Analysis of Osimertinib and Second-Generation EGFR-TKIsSemantic proximity
Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.Semantic proximity
Comprehensive Analysis of NGS And ARMS-PCR For Detecting EGFR Mutations Based On 4467 Cases of NSCLC PatientsSemantic proximity
Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry).Semantic proximity
Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.Semantic proximity
[Consensus on Application of Third-generation EGFR-TKI in EGFR Mutated NSCLC (2022 Version)].Semantic proximity
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study.Semantic proximity
Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.Semantic proximity
Clinical characteristics and treatment of EGFR exon 19 L747 mutation in advanced NSCLC: a retrospective study.Semantic proximity
Select a neighboring publication to make it the new centre.